nach oben

Neurotherapeutics

Erschienen in:

01.10.2020 | Review

Current Management and Emerging Therapies in Multiple System Atrophy

verfasst von: Matthew R. Burns, Nikolaus R. McFarland

Erschienen in: Neurotherapeutics | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Multiple system atrophy (MSA) is a progressive neurodegenerative disease variably associated with motor, nonmotor, and autonomic symptoms, resulting from putaminal and cerebellar degeneration and associated with glial cytoplasmic inclusions enriched with α-synuclein in oligodendrocytes and neurons. Although symptomatic treatment of MSA can provide significant improvements in quality of life, the benefit is often partial, limited by adverse effects, and fails to treat the underlying cause. Consistent with the multisystem nature of the disease and evidence that motor symptoms, autonomic failure, and depression drive patient assessments of quality of life, treatment is best achieved through a coordinated multidisciplinary approach driven by the patient’s priorities and goals of care. Research into disease-modifying therapies is ongoing with a particular focus on synuclein-targeted therapies among others. This review focuses on both current management and emerging therapies for this devastating disease.

Nur mit Berechtigung zugänglich

Gilman S, May SJ, Shults CW, et al. The North American Multiple System Atrophy Study Group. J Neural Transm (Vienna) 2005;112:1687-1694. https://doi.org/10.1007/s00702-005-0381-6.CrossRef

Kollensperger M, Geser F, Ndayisaba JP, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010;25:2604-2612. https://doi.org/10.1002/mds.23192.CrossRefPubMed

Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002;125:1070-1083.CrossRefPubMed

Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med 2015;372:249-263. https://doi.org/10.1056/NEJMra1311488.CrossRefPubMed

Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997;48:384-393.CrossRefPubMed

Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013;12:264-274. https://doi.org/10.1016/S1474-4422(12)70327-7.CrossRefPubMedPubMedCentral

Low PA, Reich SG, Jankovic J, et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 2015;14:710-719. https://doi.org/10.1016/S1474-4422(15)00058-7.CrossRefPubMedPubMedCentral

Foubert-Samier A, Pavy-Le Traon A, Guillet F, et al. Disease progression and prognostic factors in multiple system atrophy: a prospective cohort study. Neurobiol Dis 2020;139:104813. https://doi.org/10.1016/j.nbd.2020.104813.CrossRefPubMed

McFarland NR. Diagnostic approach to atypical parkinsonian syndromes. Continuum (Minneap Minn) 2016;22(4 Movement Disorders):1117-1142. https://doi.org/10.1212/CON.0000000000000348.CrossRef

10.

Cong S, Xiang C, Wang H, Cong S. Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis. J Neurol 2020. https://doi.org/10.1007/s00415-020-09781-9.

11.

Chelban V, Bocchetta M, Hassanein S, Haridy NA, Houlden H, Rohrer JD. An update on advances in magnetic resonance imaging of multiple system atrophy. J Neurol 2019;266:1036-1045. https://doi.org/10.1007/s00415-018-9121-3.CrossRefPubMed

12.

Jellinger KA. Multiple system atrophy: an oligodendroglioneural synucleinopathy. J Alzheimers Dis 2018;62:1141-1179. https://doi.org/10.3233/JAD-170397.CrossRefPubMedPubMedCentral

13.

Jellinger KA. Neuropathology of multiple system atrophy: new thoughts about pathogenesis. Mov Disord 2014;29:1720-1741. https://doi.org/10.1002/mds.26052.CrossRefPubMed

14.

Sato K, Kaji R, Matsumoto S, Nagahiro S, Goto S. Compartmental loss of striatal medium spiny neurons in multiple system atrophy of parkinsonian type. Mov Disord 2007;22:2365-2370. https://doi.org/10.1002/mds.21732.CrossRefPubMed

15.

Tsuchiya K, Ozawa E, Haga C, et al. Constant involvement of the Betz cells and pyramidal tract in multiple system atrophy: a clinicopathological study of seven autopsy cases. Acta Neuropathol 2000;99:628-636. https://doi.org/10.1007/s004010051173.CrossRefPubMed

16.

Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12:133-147. https://doi.org/10.1002/mds.870120203.CrossRefPubMed

17.

Jellinger KA, Lantos PL. Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update. Acta Neuropathol 2010;119:657-667. https://doi.org/10.1007/s00401-010-0672-3.CrossRefPubMed

18.

Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989;94:79-100.CrossRefPubMed

19.

Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994;117 235-243. https://doi.org/10.1093/brain/117.2.235.CrossRefPubMed

20.

Ubhi K, Low P, Masliah E. Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci 2011;34 581-590. https://doi.org/10.1016/j.tins.2011.08.003.CrossRefPubMedPubMedCentral

21.

Nishie M, Mori F, Yoshimoto M, Takahashi H, Wakabayashi K. A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy. Neuropathol Appl Neurobiol 2004;30:546-554.https://doi.org/10.1111/j.1365-2990.2004.00564.x.CrossRefPubMed

22.

Wenning GK, Jellinger KA. The role of alpha-synuclein in the pathogenesis of multiple system atrophy. Acta Neuropathol 2005;109:129-140. https://doi.org/10.1007/s00401-004-0935-y.CrossRefPubMed

23.

Ahmed Z, Asi YT, Sailer A, et al. The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 2012;38:4-24. https://doi.org/10.1111/j.1365-2990.2011.01234.x.CrossRefPubMed

24.

Bendor JT, Logan TP, Edwards RH. The function of alpha-synuclein. Neuron 2013;79:1044-1066. https://doi.org/10.1016/j.neuron.2013.09.004.CrossRefPubMed

25.

Uchihara T, Giasson BI. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 2016;131 49-73. https://doi.org/10.1007/s00401-015-1485-1CrossRefPubMed

26.

Jellinger KA, Wenning GK. Multiple system atrophy: pathogenic mechanisms and biomarkers. J Neural Transm (Vienna). 2016;123:555-572. https://doi.org/10.1007/s00702-016-1545-2CrossRef

27.

Henderson MX, Trojanowski JQ, Lee VMY. alpha-Synuclein pathology in Parkinson’s disease and related alpha-synucleinopathies. Neurosci Lett. 2019;709. https://doi.org/10.1016/j.neulet.2019.134316.

28.

Dhillon JS, Trejo-Lopez JA, Riffe C, et al. Dissecting alpha-synuclein inclusion pathology diversity in multiple system atrophy: implications for the prion-like transmission hypothesis. Lab Invest 2019;99:982-992. https://doi.org/10.1038/s41374-019-0198-9.CrossRefPubMedPubMedCentral

29.

Lau A, So RWL, Lau HHC, et al. alpha-Synuclein strains target distinct brain regions and cell types. Nat Neurosci 2020;23:21-31. https://doi.org/10.1038/s41593-019-0541-x.CrossRefPubMed

30.

Holec SAM, Woerman AL. Evidence of distinct alpha-synuclein strains underlying disease heterogeneity. Acta Neuropathol 2020. https://doi.org/10.1007/s00401-020-02163-5.

31.

Prusiner SB, Woerman AL, Mordes DA, et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A 2015. https://doi.org/10.1073/pnas.1514475112.

32.

Woerman AL, Oehler A, Kazmi SA, et al. Multiple system atrophy prions retain strain specificity after serial propagation in two different Tg(SNCA*A53T) mouse lines. Acta Neuropathol. 2019;137:437-454. https://doi.org/10.1007/s00401-019-01959-4CrossRefPubMedPubMedCentral

33.

Brundin P, Dave KD, Kordower JEH. Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol 2017;298:225-235. https://doi.org/10.1016/j.expneurol.2017.10.003.CrossRefPubMedPubMedCentral

34.

Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-98.CrossRefPubMed

35.

Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71 670-676. https://doi.org/10.1212/01.wnl.0000324625.00404.15.CrossRefPubMedPubMedCentral

36.

Kollensperger M, Geser F, Seppi K, et al. Red flags for multiple system atrophy. Mov Disord 2008;23 1093-1099. https://doi.org/10.1002/mds.21992.CrossRefPubMed

37.

Kojovic M, Cordivari C, Bhatia K. Myoclonic disorders: a practical approach for diagnosis and treatment. Ther Adv Neurol Disord 2011;4:47-62. https://doi.org/10.1177/1756285610395653.CrossRefPubMedPubMedCentral

38.

Koga S, Aoki N, Uitti RJ, et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 2015;85:404-412. https://doi.org/10.1212/WNL.0000000000001807.CrossRefPubMedPubMedCentral

39.

Joutsa J, Gardberg M, Roytta M, Kaasinen V. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord 2014;20:840-844. https://doi.org/10.1016/j.parkreldis.2014.04.019CrossRefPubMed

40.

Jabbari E, Holland N, Chelban V, et al. Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome. JAMA Neurol 2019. https://doi.org/10.1001/jamaneurol.2019.4347.

41.

Boesch SM, Wenning GK, Ransmayr G, Poewe W. Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002;72:300-303. https://doi.org/10.1136/jnnp.72.3.300.CrossRefPubMedPubMedCentral

42.

Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology 2005;65:355-359. https://doi.org/10.1212/01.wnl.0000171857.09079.9f.CrossRefPubMed

43.

Slawek J, Derejko M, Lass P, Dubaniewicz M. Camptocormia or Pisa syndrome in multiple system atrophy. Clin Neurol Neurosurg 2006;108:699-704.https://doi.org/10.1016/j.clineuro.2005.07.004.CrossRefPubMed

44.

Bhalsing K, Suresh K, Muthane UB, Pal PK. Prevalence and profile of Restless Legs Syndrome in Parkinson’s disease and other neurodegenerative disorders: a case-control study. Parkinsonism Relat Disord 2013;19 426-430. https://doi.org/10.1016/j.parkreldis.2012.12.005.CrossRefPubMed

45.

Ghorayeb I, Dupouy S, Tison F, Meissner WG. Restless legs syndrome in multiple system atrophy. J Neural Transm (Vienna) 2014;121:1523-1527. https://doi.org/10.1007/s00702-014-1232-0.CrossRef

46.

Kluin KJ, Gilman S, Lohman M, Junck L. Characteristics of the dysarthria of multiple system atrophy. Arch Neurol 1996;53 545-548. https://doi.org/10.1001/archneur.1996.00550060089021.CrossRefPubMed

47.

Rusz J, Tykalova T, Salerno G, Bancone S, Scarpelli J, Pellecchia MT. Distinctive speech signature in cerebellar and parkinsonian subtypes of multiple system atrophy. J Neurol 2019;266 1394-1404. https://doi.org/10.1007/s00415-019-09271-7.CrossRefPubMed

48.

Eschlbock S, Delazer M, Krismer F, et al. Cognition in multiple system atrophy: a single-center cohort study. Ann Clin Transl Neurol 2020;7:219-228. https://doi.org/10.1002/acn3.50987.CrossRefPubMedPubMedCentral

49.

Stankovic I, Krismer F, Jesic A, et al. Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. Mov Disord 2014;29:857-867. https://doi.org/10.1002/mds.25880.CrossRefPubMedPubMedCentral

50.

Benrud-Larson LM, Sandroni P, Schrag A, Low PA. Depressive symptoms and life satisfaction in patients with multiple system atrophy. Mov Disord 2005;20:951-957. https://doi.org/10.1002/mds.20450.CrossRefPubMed

51.

Schrag A, Geser F, Stampfer-Kountchev M, et al. Health-related quality of life in multiple system atrophy. Mov Disord 2006;21:809-815. https://doi.org/10.1002/mds.20808.CrossRefPubMed

52.

Zhang LY, Cao B, Zou YT, et al. Depression and anxiety in multiple system atrophy. Acta Neurol Scand 2018;137:33-37. https://doi.org/10.1111/ane.12804.CrossRefPubMed

53.

Almeida L, Ahmed B, Walz R, et al. Depressive symptoms are frequent in atypical Parkinsonian disorders. Mov Disord Clin Pract 2017;4 191-197. https://doi.org/10.1002/mdc3.12382.CrossRefPubMed

54.

Tison F, Yekhlef F, Chrysostome V. Depression and self-reported depressive symptoms in multiple system atrophy compared to Parkinson’s disease. Mov Disord 2006;21 1056-1057. https://doi.org/10.1002/mds.20891.CrossRefPubMed

55.

Parvizi J, Joseph J, Press DZ, Schmahmann JD. Pathological laughter and crying in patients with multiple system atrophy-cerebellar type. Mov Disord 2007;22 798-803. https://doi.org/10.1002/mds.21348.CrossRefPubMed

56.

Roncevic D, Palma JA, Martinez J, Goulding N, Norcliffe-Kaufmann L, Kaufmann H. Cerebellar and parkinsonian phenotypes in multiple system atrophy: similarities, differences and survival. J Neural Transm (Vienna) 2014;121 507-12. https://doi.org/10.1007/s00702-013-1133-7.CrossRef

57.

Iodice V, Lipp A, Ahlskog JE, et al. Autopsy confirmed multiple system atrophy cases: Mayo experience and role of autonomic function tests. J Neurol Neurosurg Psychiatry 2012;83:453-459. https://doi.org/10.1136/jnnp-2011-301068.CrossRefPubMed

58.

Sakakibara R, Hattori T, Uchiyama T, et al. Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation? J Neurol Neurosurg Psychiatry 2000;68:65-69. https://doi.org/10.1136/jnnp.68.1.65.CrossRefPubMedPubMedCentral

59.

Ito T, Sakakibara R, Yasuda K, et al. Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord 2006;21:816-823. https://doi.org/10.1002/mds.20815.CrossRefPubMed

60.

Kirchhof K, Apostolidis AN, Mathias CJ, Fowler CJ. Erectile and urinary dysfunction may be the presenting features in patients with multiple system atrophy: a retrospective study. Int J Impot Res 2003;15:293-298. https://doi.org/10.1038/sj.ijir.3901014.CrossRefPubMed

61.

Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain. 1994;117:835-845.CrossRefPubMed

62.

Coon EA, Sletten DM, Suarez MD, et al. Clinical features and autonomic testing predict survival in multiple system atrophy. Brain 2015;138:3623-3631. https://doi.org/10.1093/brain/awv274.CrossRefPubMedPubMedCentral

63.

Glasmacher SA, Leigh PN, Saha RA. Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2017;88:402-411. https://doi.org/10.1136/jnnp-2016-314956.CrossRefPubMed

64.

Xia C, Postuma RB. Diagnosing multiple system atrophy at the prodromal stage. Clin Auton Res 2020;30:197-205. https://doi.org/10.1007/s10286-020-00682-5.CrossRefPubMed

65.

Silveira-Moriyama L, Mathias C, Mason L, Best C, Quinn NP, Lees AJ. Hyposmia in pure autonomic failure. Neurology 2009;72:1677-1681. https://doi.org/10.1212/WNL.0b013e3181a55fd2.CrossRefPubMed

66.

Palma JA, Fernandez-Cordon C, Coon EA, et al. Prevalence of REM sleep behavior disorder in multiple system atrophy: a multicenter study and meta-analysis. Clin Auton Res 2015;25:69-75. https://doi.org/10.1007/s10286-015-0279-9.CrossRefPubMedPubMedCentral

67.

Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010;75:494-499. https://doi.org/10.1212/WNL.0b013e3181ec7fac.CrossRefPubMedPubMedCentral

68.

Abbott SM, Videnovic A. Sleep disorders in atypical Parkinsonism. Mov Disord Clin Pract 2014;1:89-96. https://doi.org/10.1002/mdc3.12025.CrossRefPubMedPubMedCentral

69.

Iranzo A. Sleep and breathing in multiple system atrophy. Curr Treat Options Neurol 2007;9:347-353.CrossRefPubMed

70.

Cortelli P, Calandra-Buonaura G, Benarroch EE, et al. Stridor in multiple system atrophy: consensus statement on diagnosis, prognosis, and treatment. Neurology 2019;93:630-639. https://doi.org/10.1212/WNL.0000000000008208.CrossRefPubMedPubMedCentral

71.

Kaufmann H, Norcliffe-Kaufmann L, Palma JA, Autonomic Disorders C. Reply to “Pure autonomic failure vs. manifest CNS synucleinopathy: relevance of stridor and autonomic biomarkers”. Ann Neurol 2017;81:910-911. https://doi.org/10.1002/ana.24949.CrossRefPubMedPubMedCentral

72.

Osaki Y, Ben-Shlomo Y, Lees AJ, Wenning GK, Quinn NP. A validation exercise on the new consensus criteria for multiple system atrophy. Mov Disord 2009;24:2272-2276. https://doi.org/10.1002/mds.22826.CrossRefPubMed

73.

Tha KK, Terae S, Tsukahara A, et al. Hyperintense putaminal rim at 1.5 T: prevalence in normal subjects and distinguishing features from multiple system atrophy. BMC Neurol 2012;12:39. https://doi.org/10.1186/1471-2377-12-39.CrossRefPubMedPubMedCentral

74.

Planetta PJ, Kurani AS, Shukla P, et al. Functional and macrostructural MRI in Parkinson's disease and multiple system atrophy. Mov Disord 2014;29:S90.CrossRef

75.

Planetta PJ, Kurani AS, Shukla P, et al. Distinct functional and macrostructural brain changes in Parkinson’s disease and multiple system atrophy. Hum Brain Mapp 2014. https://doi.org/10.1002/hbm.22694.

76.

Lee JH, Baik SK. Putaminal hypointensity in the parkinsonian variant of multiple system atrophy: simple visual assessment using susceptibility-weighted imaging. J Mov Disord. 2011;4:60-63. https://doi.org/10.14802/jmd.11012CrossRefPubMedPubMedCentral

77.

Sugiyama A, Sato N, Kimura Y, et al. Quantifying iron deposition in the cerebellar subtype of multiple system atrophy and spinocerebellar ataxia type 6 by quantitative susceptibility mapping. J Neurol Sci 2019;407:116525.https://doi.org/10.1016/j.jns.2019.116525.CrossRefPubMed

78.

Juh R, Kim J, Moon D, Choe B, Suh T. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur J Radiol 2004;51:223-233.https://doi.org/10.1016/S0720-048X(03)00214-6.CrossRefPubMed

79.

Perju-Dumbrava LD, Kovacs GG, Pirker S, et al. Dopamine transporter imaging in autopsy-confirmed Parkinson’s disease and multiple system atrophy. Mov Disord 2012;27:65-71. https://doi.org/10.1002/mds.24000.CrossRefPubMed

80.

Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson’s disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord 2012;18 494-500. https://doi.org/10.1016/j.parkreldis.2012.01.009.CrossRefPubMed

81.

Nagayama H, Ueda M, Yamazaki M, Nishiyama Y, Hamamoto M, Katayama Y. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov Disord 2010;25 1744-1747. https://doi.org/10.1002/mds.23338.CrossRefPubMed

82.

Nagayama H, Yamazaki M, Ueda M, et al. Low myocardial MIBG uptake in multiple system atrophy with incidental Lewy body pathology: an autopsy case report. Mov Disord 2008;23:1055-1057. https://doi.org/10.1002/mds.22031.CrossRefPubMed

83.

Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001;11:351-355. https://doi.org/10.1007/bf02292766.CrossRefPubMed

84.

Goldstein DS. Dysautonomia in Parkinson disease. Compr Physiol 2014;4805-826. https://doi.org/10.1002/cphy.c130026.

85.

Kaufmann H, Goldstein DS. Autonomic dysfunction in Parkinson disease. Handb Clin Neurol 2013;117:259-278. https://doi.org/10.1016/B978-0-444-53491-0.00021-3.CrossRefPubMed

86.

Orimo S, Oka T, Miura H, et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002;73:776-777. https://doi.org/10.1136/jnnp.73.6.776.CrossRefPubMedPubMedCentral

87.

Marques TM, Kuiperij HB, Bruinsma IB, et al. MicroRNAs in cerebrospinal fluid as potential biomarkers for Parkinson’s disease and multiple system atrophy. Mol Neurobiol 2017;54 7736-7745. https://doi.org/10.1007/s12035-016-0253-0.CrossRefPubMed

88.

Bougea A, Stefanis L, Paraskevas GP, Emmanouilidou E, Vekrelis K, Kapaki E. Plasma alpha-synuclein levels in patients with Parkinson’s disease: a systematic review and meta-analysis. Neurol Sci 2019;40:929-938. https://doi.org/10.1007/s10072-019-03738-1.CrossRefPubMed

89.

Kim JY, Illigens BM, McCormick MP, Wang N, Gibbons CH. Alpha-synuclein in skin nerve fibers as a biomarker for alpha-synucleinopathies. J Clin Neurol 2019;15 135-142. https://doi.org/10.3988/jcn.2019.15.2.135.CrossRefPubMedPubMedCentral

90.

De Luca CMG, Elia AE, Portaleone SM, et al. Efficient RT-QuIC seeding activity for alpha-synuclein in olfactory mucosa samples of patients with Parkinson's disease and multiple system atrophy. Transl Neurodegener 2019;8:24. https://doi.org/10.1186/s40035-019-0164-xCrossRefPubMedPubMedCentral

91.

Manne S, Kondru N, Jin H, et al. alpha-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson’s disease patients. Mov Disord 2020;35:268-278. https://doi.org/10.1002/mds.27907.CrossRefPubMed

92.

Vlaanderen FP, Rompen L, Munneke M, Stoffer M, Bloem BR, Faber MJ. The voice of the Parkinson customer. J Parkinsons Dis 2019;9:197-201. https://doi.org/10.3233/JPD-181431.CrossRefPubMed

93.

van der Eijk M, Faber MJ, Al Shamma S, Munneke M, Bloem BR. Moving towards patient-centered healthcare for patients with Parkinson’s disease. Parkinsonism Relat Disord 2011;17:360-364. https://doi.org/10.1016/j.parkreldis.2011.02.012.CrossRefPubMed

94.

van der Marck MA, Bloem BR, Borm GF, Overeem S, Munneke M, Guttman M. Effectiveness of multidisciplinary care for Parkinson’s disease: a randomized, controlled trial. Mov Disord 2013;28:605-611. https://doi.org/10.1002/mds.25194.CrossRefPubMed

95.

van der Marck MA, Munneke M, Mulleners W, et al. Integrated multidisciplinary care in Parkinson’s disease: a non-randomised, controlled trial (IMPACT). Lancet Neurol 2013;12 947-956. https://doi.org/10.1016/S1474-4422(13)70196-0.CrossRefPubMed

96.

van der Marck MA, Bloem BR. How to organize multispecialty care for patients with Parkinson’s disease. Parkinsonism Relat Disord 2014;20 S167-S173. https://doi.org/10.1016/S1353-8020(13)70040-3.CrossRefPubMed

97.

Tenison E, Smink A, Redwood S, et al. Proactive and integrated management and empowerment in Parkinson’s disease: designing a new model of care. Parkinsons Dis 2020;2020:8673087. https://doi.org/10.1155/2020/8673087.CrossRefPubMedPubMedCentral

98.

Jaglal SB, Guilcher SJ, Bereket T, et al. Development of a Chronic Care Model for Neurological Conditions (CCM-NC). BMC Health Serv Res 2014;14:409. https://doi.org/10.1186/1472-6963-14-409.CrossRefPubMedPubMedCentral

99.

Ouwens M, Wollersheim H, Hermens R, Hulscher M, Grol R. Integrated care programmes for chronically ill patients: a review of systematic reviews. International J Qual Health Care 2005;17(2):141-146. https://doi.org/10.1093/intqhc/mzi016.CrossRef

100.

Coleman K, Austin BT, Brach C, Wagner EH. Evidence on the Chronic Care Model in the new millennium. Health Aff (Millwood) 2009;28 75-85. https://doi.org/10.1377/hlthaff.28.1.75.CrossRef

101.

Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004;3 93-103.CrossRefPubMed

102.

Flabeau O, Meissner WG, Tison F. Multiple system atrophy: current and future approaches to management. Ther Adv Neurol Disord 2010;3 249-263. https://doi.org/10.1177/1756285610375328.CrossRefPubMedPubMedCentral

103.

Rajrut AH, Uitti RJ, Fenton ME, George D. Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 1997;3 211-214.CrossRefPubMed

104.

Wenning GK, Working Group on Atypical Parkinsonism of the Austrian Parkinson’s S. Placebo-controlled trial of amantadine in multiple-system atrophy. Clin Neuropharmacol 2005;28:225-227. https://doi.org/10.1097/01.wnf.0000183240.47960.f0.CrossRefPubMed

105.

Jain S, Dawson J, Quinn NP, Playford ED. Occupational therapy in multiple system atrophy: a pilot randomized controlled trial. Mov Disord 2004;19:1360-1364. https://doi.org/10.1002/mds.20211.CrossRefPubMed

106.

Tomlinson CL, Patel S, Meek C, et al. Physiotherapy versus placebo or no intervention in Parkinson’s disease. Cochrane Database Syst Rev 2013:CD002817. https://doi.org/10.1002/14651858.CD002817.pub4.

107.

Chou KL, Forman MS, Trojanowski JQ, Hurtig HI, Baltuch GH. Subthalamic nucleus deep brain stimulation in a patient with levodopa-responsive multiple system atrophy. Case report. J Neurosurg 2004;100 553-556. https://doi.org/10.3171/jns.2004.100.3.0553.CrossRefPubMed

108.

Lezcano E, Gomez-Esteban JC, Zarranz JJ, et al. Parkinson's disease-like presentation of multiple system atrophy with poor response to STN stimulation: a clinicopathological case report. Mov Disord 2004;19 973-977. https://doi.org/10.1002/mds.20108.CrossRefPubMed

109.

Meissner WG, Laurencin C, Tranchant C, et al. Outcome of deep brain stimulation in slowly progressive multiple system atrophy: a clinico-pathological series and review of the literature. Parkinsonism Relat Disord 2016;24:69-75. https://doi.org/10.1016/j.parkreldis.2016.01.005.CrossRefPubMed

110.

Muller J, Wenning GK, Wissel J, Seppi K, Poewe W. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol 2002;249:300-304. https://doi.org/10.1007/s004150200009.CrossRefPubMed

111.

Thobois S, Broussolle E, Toureille L, Vial C. Severe dysphagia after botulinum toxin injection for cervical dystonia in multiple system atrophy. Mov Disord 2001;16:764-765. https://doi.org/10.1002/mds.1101.CrossRefPubMed

112.

Ilg W, Bastian AJ, Boesch S, et al. Consensus paper: management of degenerative cerebellar disorders. Cerebellum 2014;13 248-268. https://doi.org/10.1007/s12311-013-0531-6.CrossRefPubMedPubMedCentral

113.

Ilg W, Synofzik M, Brotz D, Burkard S, Giese MA, Schols L. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 2009;73:1823-1830. https://doi.org/10.1212/WNL.0b013e3181c33adf.CrossRefPubMed

114.

Landers M, Adams M, Acosta K, Fox A. Challenge-oriented gait and balance training in sporadic olivopontocerebellar atrophy: a case study. J Neurol Phys Ther 2009;33 160-168. https://doi.org/10.1097/NPT.0b013e3181b511f4.CrossRefPubMed

115.

Wedge F. The impact of resistance training on balance and functional ability of a patient with multiple system atrophy. J Geriatr Phys Ther 2008;31:79-83. https://doi.org/10.1519/00139143-200831020-00007.CrossRefPubMed

116.

Colosimo C, Tiple D, Wenning GK. Management of multiple system atrophy: state of the art. J Neural Transm (Vienna) 2005;112:1695-704. https://doi.org/10.1007/s00702-005-0379-0.CrossRef

117.

Cochen De Cock V. Sleep abnormalities in multiplesystem atrophy. Curr Treat Options Neurol. 2018;20:16. https://doi.org/10.1007/s11940-018-0503-8.CrossRefPubMed

118.

Videnovic A. Management of sleep disorders in Parkinson’s disease and multiple system atrophy. Mov Disord 2017;32 659-668. https://doi.org/10.1002/mds.26918.CrossRefPubMedPubMedCentral

119.

Rohrer G, Hoglinger GU, Levin J. Symptomatic therapy of multiple system atrophy. Auton Neurosci 2018;211:26-30. https://doi.org/10.1016/j.autneu.2017.10.006.CrossRefPubMed

120.

Escriba J, Hoyo B. Alternatives to clonazepam in REM behavior disorder treatment. J Clin Sleep Med 2016;12 1193. https://doi.org/10.5664/jcsm.6068.CrossRefPubMedPubMedCentral

121.

Nonaka M, Imai T, Shintani T, Kawamata M, Chiba S, Matsumoto H. Non-invasive positive pressure ventilation for laryngeal contraction disorder during sleep in multiple system atrophy. J Neurol Sci 2006;247:53-58. https://doi.org/10.1016/j.jns.2006.03.008.CrossRefPubMed

122.

Iranzo A, Santamaria J, Tolosa E, et al. Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy. Neurology 2004;63:930-932. https://doi.org/10.1212/01.wnl.0000137043.76383.a4.CrossRefPubMed

123.

Ghorayeb I, Bioulac B, Tison F. Sleep disorders in multiple system atrophy. J Neural Transm (Vienna) 2005;112:1669-1675. https://doi.org/10.1007/s00702-005-0348-7.CrossRef

124.

Silber MH, Levine S. Stridor and death in multiple system atrophy. Mov Disord 2000;15 699-704. https://doi.org/10.1002/1531-8257(200007)15:4<699::aid-mds1015>3.0.co;2-l.CrossRefPubMed

125.

Garcia-Sanchez A, Fernandez-Navarro I, Garcia-Rio F. Central apneas and REM sleep behavior disorder as an initial presentation of multiple system atrophy. J Clin Sleep Med 2016;12:267-270. https://doi.org/10.5664/jcsm.5500.CrossRefPubMedPubMedCentral

126.

St Louis EK, Boeve AR, Boeve BF. REM sleep behavior disorder in Parkinson’s disease and other synucleinopathies. Mov Disord 2017;32:645-658. https://doi.org/10.1002/mds.27018.CrossRefPubMed

127.

Tada M, Onodera O, Tada M, et al. Early development of autonomic dysfunction may predict poor prognosis in patients with multiple system atrophy. Arch Neurol 2007;64:256-260. https://doi.org/10.1001/archneur.64.2.256.CrossRefPubMed

128.

Giannini G, Calandra-Buonaura G, Mastrolilli F, et al. Early stridor onset and stridor treatment predict survival in 136 patients with MSA. Neurology 2016;87 1375-1383. https://doi.org/10.1212/WNL.0000000000003156.CrossRefPubMed

129.

Lee HH, Seo HG, Kim KD, et al. Characteristics of early oropharyngeal dysphagia in patients with multiple system atrophy. Neurodegener Dis 2018;18:84-90. https://doi.org/10.1159/000487800CrossRefPubMed

130.

Do HJ, Seo HG, Lee HH, et al. Progression of oropharyngeal dysphagia in patients with multiple system atrophy. Dysphagia. 2020;35:24-31. https://doi.org/10.1007/s00455-019-09990-z.CrossRefPubMed

131.

Friess E, Kuempfel T, Modell S, et al. Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism Relat Disord 2006;12:432-437. https://doi.org/10.1016/j.parkreldis.2006.04.002.CrossRefPubMed

132.

Zhang Q, Yang X, Song H, Jin Y. Cognitive behavioral therapy for depression and anxiety of Parkinson’s disease: a systematic review and meta-analysis. Complement Ther Clin Pract 2020;39:101111. https://doi.org/10.1016/j.ctcp.2020.101111.CrossRefPubMed

133.

Brown RG, Lacomblez L, Landwehrmeyer BG, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010;133:2382-2393. https://doi.org/10.1093/brain/awq158CrossRefPubMed

134.

Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993;95:38-48. https://doi.org/10.1016/0002-9343(93)90230-m.CrossRefPubMed

135.

Ten Harkel AD, Van Lieshout JJ, Wieling W. Treatment of orthostatic hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone. J Intern Med 1992;232139-145. https://doi.org/10.1111/j.1365-2796.1992.tb00563.x.

136.

Schoffer KL, Henderson RD, O'Maley K, O’Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007;22:1543-1549. https://doi.org/10.1002/mds.21428.CrossRefPubMed

137.

Brooks DJ, Redmond S, Mathias CJ, Bannister R, Symon L. The effect of orthostatic hypotension on cerebral blood flow and middle cerebral artery velocity in autonomic failure, with observations on the action of ephedrine. J Neurol Neurosurg Psychiatry 1989;52 962-966. https://doi.org/10.1136/jnnp.52.8.962.CrossRefPubMedPubMedCentral

138.

Elgebaly A, Abdelazeim B, Mattar O, Gadelkarim M, Salah R, Negida A. Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension. Clin Auton Res 2016;26:171-180. https://doi.org/10.1007/s10286-016-0349-7.CrossRefPubMed

139.

Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014;83 328-335. https://doi.org/10.1212/WNL.0000000000000615.CrossRefPubMedPubMedCentral

140.

Biaggioni I, Freeman R, Mathias CJ, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension 2015;65:101-107. https://doi.org/10.1161/HYPERTENSIONAHA.114.04035.CrossRefPubMed

141.

Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (nOH306B). Mov Disord 2015;30:646-654. https://doi.org/10.1002/mds.26086.CrossRefPubMed

142.

Kaufmann H, Biaggioni I. Autonomic failure in neurodegenerative disorders. Semin Neurol 2003;23:351-363. https://doi.org/10.1055/s-2004-817719.CrossRefPubMed

143.

Biaggioni I, Arthur Hewitt L, Rowse GJ, Kaufmann H. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurol 2017;17:90. https://doi.org/10.1186/s12883-017-0867-5.CrossRefPubMedPubMedCentral

144.

Patel H, Simpson A, Palevoda G, Hale GM. Evaluating the effectiveness of atomoxetine for the treatment of primary orthostatic hypotension in adults. J Clin Hypertens (Greenwich) 2018;20 794-797. https://doi.org/10.1111/jch.13260.CrossRef

145.

Hale GM, Brenner M. Atomoxetine for orthostatic hypotension in an elderly patient over 10 weeks: a case report. Pharmacotherapy 2015;35:e141-e148. https://doi.org/10.1002/phar.1635.CrossRefPubMed

146.

Ramirez CE, Okamoto LE, Arnold AC, et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2014;64:1235-1240. https://doi.org/10.1161/HYPERTENSIONAHA.114.04225CrossRefPubMed

147.

Byun JI, Kim DY, Moon J, et al. Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension. Ann Clin Transl Neurol 2020;7:112-120. https://doi.org/10.1002/acn3.50968.CrossRefPubMed

148.

Wenning GK, Geser F, Poewe W. Therapeutic strategies in multiple system atrophy. Mov Disord 2005;20 S67-S76. https://doi.org/10.1002/mds.20543.CrossRefPubMed

149.

Nygaard I. Clinical practice. Idiopathic urgency urinary incontinence. N Engl J Med 2010;363:1156-1162. https://doi.org/10.1056/NEJMcp1003849.CrossRefPubMed

150.

Peyronnet B, Vurture G, Palma JA, et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: a retrospective cohort. Parkinsonism Relat Disord 2018;57:22-26. https://doi.org/10.1016/j.parkreldis.2018.07.005.CrossRefPubMed

151.

Gubbiotti M, Conte A, Di Stasi SM, Tambasco N, Giannantoni A. Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson’s disease: a pilot study. Ther Adv Neurol Disord 2019;12:1756286419843458. https://doi.org/10.1177/1756286419843458CrossRefPubMedPubMedCentral

152.

Athanasiou S, Pitsouni E, Grigoriadis T, Zacharakis D, Salvatore S, Serati M. Mirabegron in female patients with overactive bladder syndrome: what’s new? A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2020;251:73-82. https://doi.org/10.1016/j.ejogrb.2020.05.018.CrossRefPubMed

153.

Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol 2009;182 1453-1457. https://doi.org/10.1016/j.juro.2009.06.023.CrossRefPubMed

154.

Knuepfer S, Juenemann KP. Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice. Ther Adv Urol 2014;6:34-42. https://doi.org/10.1177/1756287213510962.CrossRefPubMedPubMedCentral

155.

Sakakibara R, Uchiyama T, Asahina M, Yoshiyama M, Yamanishi T, Hattori T. Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy. Clin Auton Res 2003;13 51-53. https://doi.org/10.1007/s10286-003-0034-5.CrossRefPubMed

156.

Mathias CJ, Fosbraey P, da Costa DF, Thornley A, Bannister R. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br Med J (Clin Res Ed) 1986;293:353-354. https://doi.org/10.1136/bmj.293.6543.353.CrossRef

157.

Fowler CJ, O’Malley KJ. Investigation and management of neurogenic bladder dysfunction. J Neurol Neurosurg Psychiatry. 2003;74 iv27-iv31. https://doi.org/10.1136/jnnp.74.suppl_4.iv27.CrossRefPubMedPubMedCentral

158.

Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371-374. https://doi.org/10.1136/jnnp.71.3.371.CrossRefPubMedPubMedCentral

159.

Sacca F, Marsili A, Quarantelli M, et al. A randomized clinical trial of lithium in multiple system atrophy. J Neurol 2013;260:458-461. https://doi.org/10.1007/s00415-012-6655-7.CrossRefPubMed

160.

Wenning GK, Krismer F, Poewe W. Rifampicin for multiple system atrophy. Lancet Neurol 2014;13 237-239. https://doi.org/10.1016/S1474-4422(14)70022-5.CrossRefPubMedPubMedCentral

161.

Schenk DB, Koller M, Ness DK, et al. First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers. Mov Disord 2017;32:211-218. https://doi.org/10.1002/mds.26878.CrossRefPubMed

162.

Heras-Garvin A, Weckbecker D, Ryazanov S, et al. Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord 2019;34:255-263. https://doi.org/10.1002/mds.27562.CrossRefPubMed

163.

Valera E, Spencer B, Mott J, et al. MicroRNA-101 modulates autophagy and oligodendroglial alpha-synuclein accumulation in multiple system atrophy. Front Mol Neurosci 2017;10:329. https://doi.org/10.3389/fnmol.2017.00329.CrossRefPubMedPubMedCentral

164.

Herrera-Vaquero M, Bouquio D, Kallab M, et al. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent alpha-synuclein in experimental multiple system atrophy. Biochim Biophys Acta Mol Basis Dis 2019;1865:165513. https://doi.org/10.1016/j.bbadis.2019.07.007.CrossRefPubMedPubMedCentral

165.

Venezia S, Refolo V, Polissidis A, Stefanis L, Wenning GK, Stefanova N. Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal alpha-synucleinopathy. Mol Neurodegener 2017;12 52. https://doi.org/10.1186/s13024-017-0195-7.CrossRefPubMedPubMedCentral

166.

Bassil F, Fernagut PO, Bezard E, et al. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci U S A 2016;113:9593-9598. https://doi.org/10.1073/pnas.1609291113CrossRefPubMedPubMedCentral

167.

Kallab M, Herrera-Vaquero M, Johannesson M, et al. Region-specific effects of immunotherapy with antibodies targeting alpha-synuclein in a transgenic model of synucleinopathy. Front Neurosci 2018;12:452. https://doi.org/10.3389/fnins.2018.00452.CrossRefPubMedPubMedCentral

168.

Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009;132 156-171.CrossRefPubMed

169.

Lee PH, Lee JE, Kim HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 2012;72:32-40. https://doi.org/10.1002/ana.23612.CrossRefPubMed

170.

Singer W, Dietz AB, Zeller AD, et al. Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy. Neurology 2019;93 e77-e87. https://doi.org/10.1212/WNL.0000000000007720CrossRefPubMedPubMedCentral

171.

Mitsui J, Koguchi K, Momose T, et al. Three-year follow-up of high-dose ubiquinol supplementation in a case of familial multiple system atrophy with compound heterozygous COQ2 mutations. Cerebellum. 2017;16 664-672. https://doi.org/10.1007/s12311-017-0846-9.CrossRefPubMedPubMedCentral

172.

Bassil F, Canron MH, Vital A, et al. Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain 2017;140 1420-1436. https://doi.org/10.1093/brain/awx044CrossRefPubMedPubMedCentral

173.

Poewe W, Seppi K, Fitzer-Attas CJ, et al. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol 2015;14:145-152. https://doi.org/10.1016/S1474-4422(14)70288-1.CrossRefPubMed

174.

Dodel R, Spottke A, Gerhard A, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 2010;25 97-107. https://doi.org/10.1002/mds.22732.CrossRefPubMed

175.

Novak P, Williams A, Ravin P, Zurkiya O, Abduljalil A, Novak V. Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol 2012;12:131. https://doi.org/10.1186/1471-2377-12-131.CrossRefPubMedPubMedCentral

176.

Vidal-Martinez G, Segura-Ulate I, Yang B, et al. FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models. Exp Neurol 2020;325:113120. https://doi.org/10.1016/j.expneurol.2019.113120.CrossRefPubMed

177.

Langerveld AJ, Mihalko D, DeLong C, Walburn J, Ide CF. Gene expression changes in postmortem tissue from the rostral pons of multiple system atrophy patients. Mov Disord 2007;22:766-777. https://doi.org/10.1002/mds.21259.CrossRefPubMed

178.

Miller DW, Johnson JM, Solano SM, Hollingsworth ZR, Standaert DG, Young AB. Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm (Vienna) 2005;112:1613-1624. https://doi.org/10.1007/s00702-005-0378-1.CrossRef

179.

Ozawa T, Okuizumi K, Ikeuchi T, Wakabayashi K, Takahashi H, Tsuji S. Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. Acta Neuropathol 2001;102:188-190. https://doi.org/10.1007/s004010100367.CrossRefPubMed

180.

Jin H, Ishikawa K, Tsunemi T, Ishiguro T, Amino T, Mizusawa H. Analyses of copy number and mRNA expression level of the alpha-synuclein gene in multiple system atrophy. J Med Dent Sci 2008;55:145-153.PubMed

181.

Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009;106:13010-13015. https://doi.org/10.1073/pnas.0903691106.CrossRefPubMedPubMedCentral

182.

Hansen C, Angot E, Bergstrom AL, et al. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011;121:715-725. https://doi.org/10.1172/JCI43366.CrossRefPubMedPubMedCentral

183.

Kisos H, Pukass K, Ben-Hur T, Richter-Landsberg C, Sharon R. Increased neuronal alpha-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling alpha-synucleinopathies. PLoS One 2012;7:e46817. https://doi.org/10.1371/journal.pone.0046817.CrossRefPubMedPubMedCentral

184.

Konno M, Hasegawa T, Baba T, et al. Suppression of dynamin GTPase decreases alpha-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy. Mol Neurodegener 2012;7:38. https://doi.org/10.1186/1750-1326-7-38.CrossRefPubMedPubMedCentral

185.

Luk KC, Kehm VM, Zhang B, O’Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 2012;209 975-986. https://doi.org/10.1084/jem.20112457.CrossRefPubMedPubMedCentral

186.

Reyes JF, Rey NL, Bousset L, Melki R, Brundin P, Angot E. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 2014;62:387-398. https://doi.org/10.1002/glia.22611.CrossRefPubMed

187.

Gwinn-Hardy K, Mehta ND, Farrer M, et al. Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol 2000;99:663-672. https://doi.org/10.1007/s004010051177.CrossRefPubMed

188.

Peelaerts W, Bousset L, Van der Perren A, et al. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015;522:340-344. https://doi.org/10.1038/nature14547.CrossRefPubMed

189.

Peng C, Gathagan RJ, Covell DJ, et al. Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies. Nature 2018;557 558-563. https://doi.org/10.1038/s41586-018-0104-4.CrossRefPubMedPubMedCentral

190.

Schwarz L, Goldbaum O, Bergmann M, Probst-Cousin S, Richter-Landsberg C. Involvement of macroautophagy in multiple system atrophy and protein aggregate formation in oligodendrocytes. J Mol Neurosci 2012;47:256-266. https://doi.org/10.1007/s12031-012-9733-5.CrossRefPubMed

191.

Tanji K, Odagiri S, Maruyama A, et al. Alteration of autophagosomal proteins in the brain of multiple system atrophy. Neurobiol Dis 2013;49:190-198. https://doi.org/10.1016/j.nbd.2012.08.017CrossRefPubMed

192.

Hasegawa T, Baba T, Kobayashi M, et al. Role of TPPP/p25 on alpha-synuclein-mediated oligodendroglial degeneration and the protective effect of SIRT2 inhibition in a cellular model of multiple system atrophy. Neurochem Int 2010;57:857-866. https://doi.org/10.1016/j.neuint.2010.09.002CrossRefPubMed

193.

Stamler D, Margaret B, Wong CH, Offman E. A first in human study of PBT434, a novel small molecule inhibitor of α-synuclein aggregation [abstract]. Mov Disord. 2019;34.

194.

Finkelstein DI, Billings JL, Adlard PA, et al. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. Acta Neuropathol Commun 2017;5 53. https://doi.org/10.1186/s40478-017-0456-2.CrossRefPubMedPubMedCentral

195.

Price DL, Koike MA, Khan A, et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease. Sci Rep 2018;8 16165. https://doi.org/10.1038/s41598-018-34490-9.CrossRefPubMedPubMedCentral

196.

Wang W, Nguyen LT, Burlak C, et al. Caspase-1 causes truncation and aggregation of the Parkinson’s disease-associated protein alpha-synuclein. Proc Natl Acad Sci U S A 2016;113:9587-9592. https://doi.org/10.1073/pnas.1610099113.CrossRefPubMedPubMedCentral

197.

Ubhi K, Rockenstein E, Mante M, et al. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 2008;19 1271-1276. https://doi.org/10.1097/WNR.0b013e32830b3661.CrossRefPubMedPubMedCentral

198.

Chui DH, Tabira T, Izumi S, Koya G, Ogata J. Decreased beta-amyloid and increased abnormal Tau deposition in the brain of aged patients with leprosy. Am J Pathol 1994;145:771-775.PubMedPubMedCentral

199.

Tomiyama T, Shoji A, Kataoka K, et al. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J Biol Chem 1996;271 6839-6844. https://doi.org/10.1074/jbc.271.12.6839.CrossRefPubMed

200.

Sarkar S, Floto RA, Berger Z, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 2005;170:1101-1111. https://doi.org/10.1083/jcb.200504035.CrossRefPubMedPubMedCentral

201.

Lu SZ, Guo YS, Liang PZ, et al. Suppression of astrocytic autophagy by alphaB-crystallin contributes to alpha-synuclein inclusion formation. Transl Neurodegener 2019;8:3. https://doi.org/10.1186/s40035-018-0143-7.CrossRefPubMedPubMedCentral

202.

Li XZ, Chen XP, Zhao K, Bai LM, Zhang H, Zhou XP. Therapeutic effects of valproate combined with lithium carbonate on MPTP-induced parkinsonism in mice: possible mediation through enhanced autophagy. Int J Neurosci 2013;123 73-79. https://doi.org/10.3109/00207454.2012.729234.CrossRefPubMed

203.

Stefanova N, Reindl M, Neumann M, Kahle PJ, Poewe W, Wenning GK. Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov Disord 2007;22:2196-2203. https://doi.org/10.1002/mds.21671.CrossRefPubMed

204.

Bruck D, Wenning GK, Stefanova N, Fellner L. Glia and alpha-synuclein in neurodegeneration: a complex interaction. Neurobiol Dis 2016;85:262-274. https://doi.org/10.1016/j.nbd.2015.03.003.CrossRefPubMed

205.

Mandler M, Valera E, Rockenstein E, et al. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener 2015;10:10. https://doi.org/10.1186/s13024-015-0008-9.CrossRefPubMedPubMedCentral

206.

Mandler M, Valera E, Rockenstein E, et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials. Acta Neuropathol 2014;127:861-879. https://doi.org/10.1007/s00401-014-1256-4.CrossRefPubMedPubMedCentral

207.

Schneeberger A, Tierney L, Mandler M. Active immunization therapies for Parkinson’s disease and multiple system atrophy. Mov Disord 2016;31:214-224. https://doi.org/10.1002/mds.26377.CrossRefPubMed

208.

Bae EJ, Lee HJ, Rockenstein E, et al. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci. 2012;32:13454-13469. https://doi.org/10.1523/JNEUROSCI.1292-12.2012.CrossRefPubMedPubMedCentral

209.

Masliah E, Rockenstein E, Mante M, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 2011;6:e19338. https://doi.org/10.1371/journal.pone.0019338.CrossRefPubMedPubMedCentral

210.

Games D, Valera E, Spencer B, et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models. J Neurosci 2014;34 9441-9454. https://doi.org/10.1523/JNEUROSCI.5314-13.2014.CrossRefPubMedPubMedCentral

211.

Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;377 1723-1732. https://doi.org/10.1056/NEJMoa1702752.CrossRefPubMed

212.

DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9 https://doi.org/10.1126/scitranslmed.aag04819/374/eaag0481.

213.

DeVos SL, Miller TM. Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics 2013;10 486-97. https://doi.org/10.1007/s13311-013-0194-5.CrossRefPubMedPubMedCentral

214.

Zhao HT, John N, Delic V, et al. LRRK2 antisense oligonucleotides ameliorate alpha-synuclein inclusion formation in a Parkinson’s disease mouse model. Mol Ther Nucleic Acids 2017;8:508-519. https://doi.org/10.1016/j.omtn.2017.08.002.CrossRefPubMedPubMedCentral

215.

Alarcon-Aris D, Recasens A, Galofre M, et al. Selective alpha-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for Parkinson’s disease. Mol Ther 2018;26:550-567. https://doi.org/10.1016/j.ymthe.2017.11.015.CrossRefPubMed

216.

Scoles DR, Pulst SM. Antisense therapies for movement disorders. Mov Disord 2019;34:1112-1119. https://doi.org/10.1002/mds.27782.CrossRefPubMed

217.

Scherfler C, Sather T, Diguet E, et al. Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). J Neural Transm (Vienna) 2005;112 1025-1033. https://doi.org/10.1007/s00702-004-0245-5.CrossRef

218.

Heo JH, Lee ST, Chu K, Kim M. The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy. J Neurol Sci 2008;271:87-90. https://doi.org/10.1016/j.jns.2008.03.016CrossRefPubMed

219.

Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361:1268-1278. https://doi.org/10.1056/NEJMoa0809335.CrossRefPubMed

220.

Jenner P, Langston JW. Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Mov Disord 2011;26:2316-23. https://doi.org/10.1002/mds.23926.CrossRefPubMed

221.

Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol 2008;210:421-427. https://doi.org/10.1016/j.expneurol.2007.11.022CrossRefPubMed

222.

Gasmi M, Herzog CD, Brandon EP, et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson’s disease. Mol Ther 2007;15 62-68. https://doi.org/10.1038/sj.mt.6300010CrossRefPubMed

223.

Johnston LC, Eberling J, Pivirotto P, et al. Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther. 2009;20 (5):497-510. https://doi.org/10.1089/hum.2008.137CrossRefPubMedPubMedCentral

224.

Kohl Z, Winner B, Ubhi K, et al. Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model. Eur J Neurosci 2012;35 10-19. https://doi.org/10.1111/j.1460-9568.2011.07933.x.CrossRefPubMedPubMedCentral

225.

Ubhi K, Inglis C, Mante M, et al. Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of alpha-synucleinopathy. Exp Neurol 2012;234 405-416. https://doi.org/10.1016/j.expneurol.2012.01.008CrossRefPubMedPubMedCentral

226.

Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006;38 515-517. https://doi.org/10.1038/ng1769.CrossRefPubMed

227.

Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 2000;3 1301-1306. https://doi.org/10.1038/81834.CrossRefPubMed

228.

Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson’s disease. Lancet Neurol 2008;7 97-109. https://doi.org/10.1016/S1474-4422(07)70327-7.CrossRefPubMed

229.

Schapira AH. Mitochondrial myopathies. BMJ 1989;298:1127-1128. https://doi.org/10.1136/bmj.298.6681.1127.CrossRefPubMedPubMedCentral

230.

Singer TP, Salach JI, Castagnoli N, Jr., Trevor A. Interactions of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidases. Biochem J 1986;235 785-789. https://doi.org/10.1042/bj2350785.CrossRefPubMedPubMedCentral

231.

Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017;390 1664-1675. https://doi.org/10.1016/S0140-6736(17)31585-4.CrossRefPubMedPubMedCentral

232.

Stefanova N, Georgievska B, Eriksson H, Poewe W, Wenning GK. Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Neurotox Res 2012;21 393-404. https://doi.org/10.1007/s12640-011-9294-3.CrossRefPubMed

233.

Dezawa M, Kanno H, Hoshino M, et al. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest 2004;113:1701-1710. https://doi.org/10.1172/JCI20935.CrossRefPubMedPubMedCentral

234.

Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006;98:1076-1084. https://doi.org/10.1002/jcb.20886.CrossRefPubMed

235.

Park HJ, Bang G, Lee BR, Kim HO, Lee PH. Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy parkinsonism. Cell Transplant 2011;20:827-835. https://doi.org/10.3727/096368910X540630.CrossRefPubMed

236.

Stemberger S, Jamnig A, Stefanova N, Lepperdinger G, Reindl M, Wenning GK. Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and neuroprotection. PLoS One 2011;6:e19808. https://doi.org/10.1371/journal.pone.0019808.CrossRefPubMedPubMedCentral

237.

Lee PH, An YS, Yong SW, Yoon SN. Cortical metabolic changes in the cerebellar variant of multiple system atrophy: a voxel-based FDG-PET study in 41 patients. Neuroimage 2008;40:796-801. https://doi.org/10.1016/j.neuroimage.2007.11.055.CrossRefPubMed

238.

Garrido-Mesa N, Zarzuelo A, Galvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol 2013;169 337-52. https://doi.org/10.1111/bph.12139.CrossRefPubMedPubMedCentral

239.

Diguet E, Gross CE, Tison F, Bezard E. Rise and fall of minocycline in neuroprotection: need to promote publication of negative results. Exp Neurol 2004;189 1-4. https://doi.org/10.1016/j.expneurol.2004.05.016.CrossRefPubMed

240.

Stefanova N, Mitschnigg M, Ghorayeb I, et al. Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. J Neurosci Res 2004;78 87-91. https://doi.org/10.1002/jnr.20233.CrossRefPubMed

Titel: Current Management and Emerging Therapies in Multiple System Atrophy
verfasst von: Matthew R. Burns
Nikolaus R. McFarland
Publikationsdatum: 01.10.2020
Verlag: Springer International Publishing
Erschienen in: Neurotherapeutics / Ausgabe 4/2020
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI: https://doi.org/10.1007/s13311-020-00890-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Cortical Mechanisms of Single-Pulse Transcranial Magnetic Stimulation in Migraine

Managing Essential Tremor

Current Perspectives on Aerobic Exercise in People with Parkinson’s Disease

Rhoj Is a Novel Target for Progression and Invasion of Glioblastoma by Impairing Cytoskeleton Dynamics

Modulation of the Microbiome in Parkinson’s Disease: Diet, Drug, Stool Transplant, and Beyond